SEQ 1274
Alternative Names: SEQ-1274Latest Information Update: 22 Sep 2023
At a glance
- Originator Sequoia Sciences
- Class Antineoplastics; Small molecules
- Mechanism of Action Microtubule protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Ovarian cancer; Uterine cancer
Most Recent Events
- 17 Sep 2023 Preclinical trials in Ovarian cancer in USA (unspecified route) (Sequoia Sciences pipeline; September 2023)
- 17 Sep 2023 Preclinical trials in Uterine cancer in USA (unspecified route) (Sequoia Sciences pipeline; September 2023)
- 17 Sep 2023 Sequoia Sciences plans a clinical trials in Cancer in 2025 (Sequoia Sciences pipeline; September 2023)